SG11201808907PA - Inhibitors of activin receptor-like kinase - Google Patents
Inhibitors of activin receptor-like kinaseInfo
- Publication number
- SG11201808907PA SG11201808907PA SG11201808907PA SG11201808907PA SG11201808907PA SG 11201808907P A SG11201808907P A SG 11201808907PA SG 11201808907P A SG11201808907P A SG 11201808907PA SG 11201808907P A SG11201808907P A SG 11201808907PA SG 11201808907P A SG11201808907P A SG 11201808907PA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- cambridge
- boston
- compounds
- pct
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization MD 1111101110101011111 HO 11111 011101111110101 010 111111111011011# International Bureau 0.. .... .. (10) International Publication Number (43) International Publication Date ..... ...,/ WO 2017/181117 Al 19 October 2017(19.10.2017) WIPO I PCT (51) International Patent Classification: Ayer, MA 01432 (US). WILSON, Kevin, J.; 38 Union C07D 487/04 (2006.01) A61K 31/5025 (2006.01) Park, Apt. 4, Boston, MA 02118 (US). C07D 519/00 (2006.01) A61P 19/00 (2006.01) (74) Agent: GEORGES EVANGELINOS, Asimina, T.; (21) International Application Number: Lando & Anastasi, LLP, Riverton Office Park, One Main PCT/US2017/027775 Street, Suite 1100, Cambridge, MA 02142 (US). (22) International Filing Date: (81) Designated States (unless otherwise indicated, for every 14 April 2017 (14.04.2017) kind AO, of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (25) Filing Language: English BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (26) Publication Language: English DO, HN, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, (30) Priority Data: KP, 62/322,948 15 April 2016 (15.04.2016) US MD, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, 62/411,172 21 October 2016 (21.10.2016) US NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (71) Applicant: BLUEPRINT MEDICINES CORPORA- RU, TION [US/US]; 38 Sidney Street, Suite 200, Cambridge, TH, MA 02139 (US). ZA, ZM, ZW. RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (72) Inventors: BROOIJMANS, Natasja; 43 Concord Square, (84) Designated States (unless otherwise indicated, for every Apt. 2, Boston, MA 02118 (US). BRUBAKER, Jason, D.; kind 26 Sciarappa St Unit 1, Cambridge, MA 02141 (US). GM, TZ, of regional protection available): ARIPO (BW, GH, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (72) Inventor: CRONIN, Mark (deceased). TJ, DK, Inventors: FLEMING, Paul, E.; 7 Sunnyside Ave, LV, Wellesley, MA 02482 (US). HODOUS, Brian, L.; 250 (72) TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, Chestnut Street, Cambridge, MA 02139 (US). KIM, GW, KM, ML, MR, NE, SN, TD, TG). Joseph, L.; 20 Green Way, Wayland, MA 01778 (US). TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, WAETZIG, Josh; 30 Livermore Road, Waltham, MA Published: 02451 (US). WILLIAMS, Brett; 24 Castleton St., Boston, with MA 02130 (US). WILSON, Douglas; 33 Mulberry Circle, international search report (Art. 21(3)) 1-1 IN 11 11 11 GC 11 IN 11 © ei (54) Title: INHIBITORS OF ACTWIN RECEPTOR-LIKE K1NASE C ) ,.. (57) : Described herein are compounds that inhibit ALK2 and its mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662322948P | 2016-04-15 | 2016-04-15 | |
| US201662411172P | 2016-10-21 | 2016-10-21 | |
| PCT/US2017/027775 WO2017181117A1 (en) | 2016-04-15 | 2017-04-14 | Inhibitors of activin receptor-like kinase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201808907PA true SG11201808907PA (en) | 2018-11-29 |
Family
ID=59215888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201808907PA SG11201808907PA (en) | 2016-04-15 | 2017-04-14 | Inhibitors of activin receptor-like kinase |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US10233186B2 (en) |
| EP (2) | EP4285996A3 (en) |
| JP (1) | JP7017521B2 (en) |
| KR (1) | KR102426043B1 (en) |
| CN (1) | CN109311889B (en) |
| AU (1) | AU2017250302B2 (en) |
| BR (1) | BR112018071184A2 (en) |
| CA (1) | CA3020870A1 (en) |
| CL (1) | CL2018002945A1 (en) |
| DK (1) | DK3442977T3 (en) |
| ES (1) | ES2957233T3 (en) |
| FI (1) | FI3442977T3 (en) |
| HU (1) | HUE063042T2 (en) |
| IL (1) | IL262345B (en) |
| MX (1) | MX2018012664A (en) |
| PH (1) | PH12018502205A1 (en) |
| PL (1) | PL3442977T3 (en) |
| PT (1) | PT3442977T (en) |
| SG (1) | SG11201808907PA (en) |
| WO (1) | WO2017181117A1 (en) |
| ZA (2) | ZA201807256B (en) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2872491B1 (en) | 2012-07-11 | 2021-05-05 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
| KR102334260B1 (en) | 2013-03-14 | 2021-12-02 | 스미토모 다이니폰 파마 온콜로지, 인크. | Jak2 and alk2 inhibitors and methods for their use |
| US9499522B2 (en) | 2013-03-15 | 2016-11-22 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| PL3057969T3 (en) | 2013-10-17 | 2018-11-30 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| KR102405452B1 (en) | 2013-10-25 | 2022-06-03 | 블루프린트 메디신즈 코포레이션 | Inhibitors of the fibroblast growth factor receptor |
| US9695165B2 (en) | 2014-01-15 | 2017-07-04 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
| US10202365B2 (en) | 2015-02-06 | 2019-02-12 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors |
| AU2016297754A1 (en) | 2015-07-24 | 2018-02-15 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to KIT and PDGFR |
| WO2017035354A1 (en) | 2015-08-26 | 2017-03-02 | Blueprint Medicines Corporation | Compounds and compositions useful for treating disorders related to ntrk |
| AU2016348402B2 (en) | 2015-11-02 | 2021-05-13 | Blueprint Medicines Corporation | Inhibitors of RET |
| CA3005741A1 (en) | 2015-11-19 | 2017-05-26 | Blueprint Medicines Corporation | Compounds and compositions useful for treating disorders related to ntrk |
| WO2017161269A1 (en) | 2016-03-17 | 2017-09-21 | Blueprint Medicines Corporation | Inhibitors of ret receptor tyrosine kinases |
| AU2017251537B2 (en) | 2016-04-15 | 2020-10-08 | Abbvie Inc. | Bromodomain inhibitors |
| DK3442977T3 (en) | 2016-04-15 | 2023-10-09 | Blueprint Medicines Corp | ACTIVIN RECEPTOR-LIKE KINASE INHIBITORS |
| WO2018017983A1 (en) | 2016-07-22 | 2018-01-25 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to ret |
| US10035789B2 (en) | 2016-07-27 | 2018-07-31 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to RET |
| US11040979B2 (en) | 2017-03-31 | 2021-06-22 | Blueprint Medicines Corporation | Substituted pyrrolo[1,2-b]pyridazines for treating disorders related to KIT and PDGFR |
| WO2018195450A1 (en) | 2017-04-21 | 2018-10-25 | Epizyme, Inc. | Combination therapies with ehmt2 inhibitors |
| CN109081828B (en) * | 2017-06-14 | 2021-03-26 | 上海时莱生物技术有限公司 | Poly (ADP-ribose) polymerase inhibitor, preparation method and application |
| ES2931537T3 (en) | 2017-10-18 | 2022-12-30 | Blueprint Medicines Corp | Substituted pyrrolopyridines as activin receptor-like kinase inhibitors |
| SG11202009681YA (en) | 2018-04-03 | 2020-10-29 | Blueprint Medicines Corp | Ret inhibitor for use in treating cancer having a ret alteration |
| US11040038B2 (en) | 2018-07-26 | 2021-06-22 | Sumitomo Dainippon Pharma Oncology, Inc. | Methods for treating diseases associated with abnormal ACVR1 expression and ACVR1 inhibitors for use in the same |
| CN109456253B (en) * | 2019-01-11 | 2020-04-07 | 上海博璞诺科技发展有限公司 | Method for synthesizing (S) -3- (4-bromophenyl) -piperidine or salt thereof through chiral induction |
| US20220281879A1 (en) * | 2019-08-13 | 2022-09-08 | Blueprint Medicines Corporation | Salt and crystal forms of an activin receptor-like kinase inhibitor |
| CN114502558A (en) * | 2019-10-02 | 2022-05-13 | 缆图药品公司 | Method for preparing activin receptor-like kinase inhibitors |
| CN110698388A (en) * | 2019-11-01 | 2020-01-17 | 暨明医药科技（苏州）有限公司 | Method for industrially producing (S) -3- (4-bromophenyl) piperidine |
| IL303812A (en) * | 2020-12-21 | 2023-08-01 | Biocryst Pharm Inc | Dosing regimens for oral alk2 kinase inhibitors |
| EP4274832A1 (en) * | 2021-01-07 | 2023-11-15 | Biogen MA Inc. | Tyk2 inhibitors |
| WO2023247670A1 (en) * | 2022-06-24 | 2023-12-28 | F. Hoffmann-La Roche Ag | New heterocyclic-carbonyl-cyclic compounds as magl inhibitors |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005209115A1 (en) | 2004-01-30 | 2005-08-11 | Japan Tobacco Inc. | Anorectic compounds |
| CA2695989A1 (en) | 2007-08-10 | 2009-02-19 | Glaxosmithkline Llc | Certain nitrogen containing bicyclic chemical entities for treating viral infections |
| AR070127A1 (en) | 2008-01-11 | 2010-03-17 | Novartis Ag | PIRROLO - PIRIMIDINAS AND PIRROLO -PIRIDINAS |
| KR101792837B1 (en) * | 2009-04-16 | 2017-11-02 | 푼다시온 센트로 나시오날 드 인베스티가시오네스 온콜로기카스 카를로스Ⅲ | Imidazopyrazines for use as kinase inhibitors |
| AR077428A1 (en) | 2009-07-29 | 2011-08-24 | Sanofi Aventis | (AZA) INDOLIZINACARBOXAMIDAS ITS PREPARATION AND ITS USE AS PHARMACEUTICAL AGENTS |
| KR102085121B1 (en) * | 2012-03-09 | 2020-03-05 | 렉시컨 파마슈티컬스 인코퍼레이티드 | Imidazo[1,2-b]pyridazine-based compounds, compositions comprising them, and uses thereof |
| EP2838900B1 (en) | 2012-04-17 | 2019-08-21 | Gilead Sciences, Inc. | Compounds and methods for antiviral treatment |
| JP6182593B2 (en) | 2012-04-20 | 2017-08-16 | アドヴィーナス セラピューティクス リミテッド | Substituted heterobicyclic compounds, compositions and medicaments and uses thereof |
| EP2872491B1 (en) | 2012-07-11 | 2021-05-05 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
| TWI629266B (en) | 2012-12-28 | 2018-07-11 | 藍印藥品公司 | Inhibitors of the fibroblast growth factor receptor |
| JP2016510745A (en) | 2013-03-04 | 2016-04-11 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． | BMP inhibitor and method of using the same |
| KR102334260B1 (en) | 2013-03-14 | 2021-12-02 | 스미토모 다이니폰 파마 온콜로지, 인크. | Jak2 and alk2 inhibitors and methods for their use |
| WO2014139328A1 (en) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Pyrrolo[2,3-b]pyridine cdk9 kinase inhibitors |
| US8957078B2 (en) | 2013-03-15 | 2015-02-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| US9499522B2 (en) | 2013-03-15 | 2016-11-22 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| WO2015058129A1 (en) | 2013-10-17 | 2015-04-23 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| PL3057969T3 (en) | 2013-10-17 | 2018-11-30 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| KR102405452B1 (en) | 2013-10-25 | 2022-06-03 | 블루프린트 메디신즈 코포레이션 | Inhibitors of the fibroblast growth factor receptor |
| US9695165B2 (en) | 2014-01-15 | 2017-07-04 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
| TW201613916A (en) | 2014-06-03 | 2016-04-16 | Gilead Sciences Inc | TANK-binding kinase inhibitor compounds |
| US9688680B2 (en) | 2014-08-04 | 2017-06-27 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| CA2957017A1 (en) | 2014-08-05 | 2016-02-11 | Alios Biopharma, Inc. | Combination therapy for treating a paramyxovirus |
| US10202365B2 (en) | 2015-02-06 | 2019-02-12 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors |
| US10179777B2 (en) | 2015-04-16 | 2019-01-15 | Merck Patent Gmbh | 3-(1H-benzimidazol-2-yl)-1H-pyridin-2-one derivatives |
| AU2016297754A1 (en) | 2015-07-24 | 2018-02-15 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to KIT and PDGFR |
| WO2017035354A1 (en) | 2015-08-26 | 2017-03-02 | Blueprint Medicines Corporation | Compounds and compositions useful for treating disorders related to ntrk |
| AU2016348402B2 (en) | 2015-11-02 | 2021-05-13 | Blueprint Medicines Corporation | Inhibitors of RET |
| CA3005741A1 (en) | 2015-11-19 | 2017-05-26 | Blueprint Medicines Corporation | Compounds and compositions useful for treating disorders related to ntrk |
| WO2017161269A1 (en) | 2016-03-17 | 2017-09-21 | Blueprint Medicines Corporation | Inhibitors of ret receptor tyrosine kinases |
| DK3442977T3 (en) | 2016-04-15 | 2023-10-09 | Blueprint Medicines Corp | ACTIVIN RECEPTOR-LIKE KINASE INHIBITORS |
| WO2018017983A1 (en) | 2016-07-22 | 2018-01-25 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to ret |
| US10035789B2 (en) | 2016-07-27 | 2018-07-31 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to RET |
| US20190192522A1 (en) | 2016-09-08 | 2019-06-27 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor 4 in combination with cyclin-dependent kinase inhibitors |
| US10280172B2 (en) * | 2016-09-29 | 2019-05-07 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
-
2017
- 2017-04-14 DK DK17733108.9T patent/DK3442977T3/en active
- 2017-04-14 PL PL17733108.9T patent/PL3442977T3/en unknown
- 2017-04-14 PT PT177331089T patent/PT3442977T/en unknown
- 2017-04-14 US US15/488,257 patent/US10233186B2/en active Active
- 2017-04-14 MX MX2018012664A patent/MX2018012664A/en unknown
- 2017-04-14 FI FIEP17733108.9T patent/FI3442977T3/en active
- 2017-04-14 HU HUE17733108A patent/HUE063042T2/en unknown
- 2017-04-14 EP EP23181727.1A patent/EP4285996A3/en active Pending
- 2017-04-14 KR KR1020187032927A patent/KR102426043B1/en active IP Right Grant
- 2017-04-14 SG SG11201808907PA patent/SG11201808907PA/en unknown
- 2017-04-14 CN CN201780035906.9A patent/CN109311889B/en active Active
- 2017-04-14 WO PCT/US2017/027775 patent/WO2017181117A1/en active Application Filing
- 2017-04-14 EP EP17733108.9A patent/EP3442977B1/en active Active
- 2017-04-14 CA CA3020870A patent/CA3020870A1/en active Pending
- 2017-04-14 JP JP2018553961A patent/JP7017521B2/en active Active
- 2017-04-14 ES ES17733108T patent/ES2957233T3/en active Active
- 2017-04-14 BR BR112018071184-5A patent/BR112018071184A2/en active Search and Examination
- 2017-04-14 AU AU2017250302A patent/AU2017250302B2/en active Active
-
2018
- 2018-10-14 IL IL262345A patent/IL262345B/en unknown
- 2018-10-15 PH PH12018502205A patent/PH12018502205A1/en unknown
- 2018-10-16 CL CL2018002945A patent/CL2018002945A1/en unknown
- 2018-10-30 ZA ZA2018/07256A patent/ZA201807256B/en unknown
-
2019
- 2019-03-05 US US16/293,317 patent/US10669277B2/en active Active
-
2020
- 2020-05-29 US US16/887,262 patent/US11634422B2/en active Active
- 2020-08-27 ZA ZA2020/05341A patent/ZA202005341B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201808907PA (en) | Inhibitors of activin receptor-like kinase | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201809714TA (en) | Piperidines as menin inhibitors | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201808799SA (en) | Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201804934PA (en) | Novel Compounds | |
| SG11201810983PA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG11201900344YA (en) | Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor | |
| SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
| SG11201906883SA (en) | Methods for the administration of certain vmat2 inhibitors | |
| SG11201804758QA (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
| SG11201810509PA (en) | Anti-pd-l1 antibodies | |
| SG11201902938TA (en) | Compounds, devices, and uses thereof | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201803906PA (en) | Control of cellular redox levels | |
| SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201804223TA (en) | OCTAHYDROPYRROLO [3, 4-c] PYRROLE DERIVATIVES AND USES THEREOF |